The first ophthalmic drug of Haohai BiologicalTechnology! The first homemade moxifloxacin hydrochloride eye drops approved by NMPA for registration

On March 10, moxifloxacin hydrochloride eye drops for bacterial conjunctivitis treatment under Haohai Biological Technology was approved the National Medical Products Administration (“NMPA”) for registration and marketing, as the first ophthalmic drug of Haohai Biological Technology ever approved. So far, Haohai Biological Technology is also the first homemade manufacturer to complete registration of generic drug of moxifloxacin hydrochloride eye drops in China. 

Moxifloxacin hydrochloride eye drops is the 4th-generation fluoroquinolones, one of the drugs used for bacterial conjunctivitis treatment, and compared with the currently most-widely-used 3rd-generation fluoroquinolones — levofloxacin eye drops, moxifloxacin hydrochloride eye drops is remarkably advantageous in terms of broad-spectrum antibacterial property, efficacy, drug resistance and safety, among others. 

In recent years, China’s ophthalmic drug market has been growing rapidly. According to menet.com.cn data, in 2019, the size of market for end-use ophthalmic medications at public medical institutions in China reached 11.0 billion Yuan in 2019, 14.83% up year-on-year, an indication of fast growth. Of them, anti-infection ophthalmic drugs (including moxifloxacin and levofloxacin) are the second largest ophthalmic drug category, accounting for 17.82% of the entire ophthalmic medication market. The marketing of the first generic ophthalmic drug moxifloxacin hydrochloride eye drops developed by Haohai Biological Technology alone will facilitate the presence of Haohai Biological Technology in markets for anti-infection ophthalmic drugs.